Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose IL-2 in Children with Rheumatic Diseases
NCT04397107Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Aug 2020
- Primary completion
- May 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Randomised, open-label trial of aldesleukin in systemic lupus erythematosus (SLE), primary Sjögren syndrome and juvenile idiopathic arthritis (JIA) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Change in steroid dose and immunosuppressor dose at 1 year compared to control group. Started Aug 2020; status: completed.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)primary Sjögren syndromejuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT04397107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397107.